Renal Angiomyolipoma: Causes, Symptoms, and Treatment

Renal angiomyolipomas are benign kidney tumors made up of blood vessels, smooth muscle, and fat. They arise from a specific cell type called the perivascular epithelioid cell and are driven almost entirely by mutations in one of two genes, TSC1 or TSC2, which normally keep cell growth in check. Most are small, produce no symptoms, and are discovered by accident during imaging for something else. But they can grow large enough to bleed spontaneously, and in rare subtypes they carry genuine malignant potential, so understanding when to watch and when to act matters.

What Causes Them

The root cause of renal angiomyolipomas is the loss of function in TSC1 or TSC2, two genes that act as brakes on a growth-signaling pathway called mTOR. When both copies of one of these genes are knocked out in a kidney cell, mTOR signaling runs unchecked, and the cell begins dividing and differentiating in abnormal ways. A whole-exome sequencing study found that TSC2 mutations (and less commonly TSC1 mutations) are the primary and sufficient driver event, with other somatic mutations being rare and unlikely to contribute to tumor development.¹ This is an unusually clean genetic picture for a tumor; in most cancers, dozens of mutations accumulate over time, but angiomyolipomas appear to need just this one event.

Some people carry a germline (inherited) mutation in TSC1 or TSC2 throughout their body. This causes tuberous sclerosis complex, a genetic condition that affects roughly 1 in 6,000 births. People with TSC develop angiomyolipomas at high rates, often bilaterally and in multiple numbers, because every kidney cell already has one defective copy of the gene and only needs to lose the second. In people without TSC, angiomyolipomas are called “sporadic.” They occur when a kidney cell independently acquires mutations in both copies of TSC1 or TSC2 over a lifetime. The end result at the cellular level is the same.

Laboratory modeling has shown that when TSC1 or TSC2 is deleted from human stem cells and those cells are pushed to differentiate into kidney tissue, they display what researchers call “lineage infidelity,” staining positive for fat-cell and pigment-cell markers that normal kidney cells never express. The resulting growths are architecturally disorganized and show overactive mTOR signaling, closely resembling human angiomyolipomas.² This confused cell identity explains why the tumor contains such a strange mix of tissues: blood vessels, muscle, and fat all growing together in a single mass.

Who Gets Them and Why Women Are Affected More Often

Renal angiomyolipomas show up more frequently in women than in men. The reason is not fully understood, but the tumors themselves appear to respond to female sex hormones. Investigations into hormone receptor expression have found that a meaningful fraction of angiomyolipomas test positive for estrogen and progesterone receptors.³ One study of 67 cases found estrogen receptors in about 42% of them, with the receptors being significantly more common in a particular subtype called the epithelioid variant.⁴

The clinical implication is that conditions involving high estrogen levels can accelerate tumor growth. There are documented cases of angiomyolipomas enlarging rapidly during ovarian stimulation therapy for fertility treatment.⁵ Pregnancy poses a particular concern and is discussed later in this article. Outside of TSC, sporadic angiomyolipomas are most often diagnosed in middle-aged adults, and many are found incidentally when someone gets a CT scan or ultrasound for unrelated abdominal symptoms.

Symptoms and Warning Signs

Small angiomyolipomas are almost always silent. The tumors become symptomatic mainly when they grow large enough to press on surrounding kidney tissue, develop internal aneurysms, or bleed. Flank pain is the most common complaint. In a series of patients presenting with large, bleeding angiomyolipomas, all reported flank pain, though visible blood in the urine was present in only a minority.⁶ A palpable mass, if detectable at all, tends to appear only when tumors reach considerable size.

The most feared complication is spontaneous hemorrhage into the space behind the kidneys, a condition called Wunderlich syndrome. The risk of this bleeding increases with the size of the tumor, the presence of aneurysms within it, and whether the patient has TSC.⁷ Tumors larger than about 4 cm are generally considered to carry enough bleeding risk to warrant active monitoring, and those with visible aneurysms on imaging attract even closer attention. When hemorrhage does occur, it can cause a sudden drop in blood pressure, severe pain, and a medical emergency requiring urgent intervention.

How They Are Diagnosed

The classic angiomyolipoma is one of the easiest kidney tumors to identify on imaging because of its fat content. Fat shows up as a distinctly low-density signal on CT scans and produces characteristic patterns on MRI. When a kidney mass clearly contains bulk fat, the diagnosis is straightforward and often does not require a biopsy.⁸

The problem arises with fat-poor and fat-invisible variants. Radiologists now classify angiomyolipomas into three categories based on how much fat is detectable: fat-rich, fat-poor, and fat-invisible.⁹ Each of these subtypes can overlap in appearance with different types of kidney cancer on scans, making the distinction clinically important.¹⁰ A mass that looks solid and lacks visible fat on CT could be a harmless angiomyolipoma or a renal cell carcinoma, and the two demand very different management.

Researchers have explored shape-based clues to help tell them apart. Some lipid-poor angiomyolipomas show an angular interface with the surrounding kidney or a characteristic oval-to-bean shape. In one study, these shape signs were highly specific for angiomyolipoma (around 95%), meaning that when present they strongly point toward a benign diagnosis, but sensitivity was poor (around 30–39%), meaning many fat-poor angiomyolipomas do not display these shapes at all.¹¹ In practice, this means that when imaging is ambiguous, a biopsy or surgical removal may still be needed to confirm the diagnosis.

When tissue is obtained, pathologists use immunohistochemical stains to confirm the diagnosis. Angiomyolipoma cells react positively to markers like HMB45 and melan-A, which are melanocyte-associated markers not typically found in normal kidney cells or kidney cancers. This staining pattern reliably distinguishes angiomyolipomas from other kidney tumors.¹²

When Watching Is Enough

For many angiomyolipomas, the best treatment is regular imaging and no intervention. The threshold that most guidelines use is around 4 cm: below that size and without symptoms, periodic imaging (usually ultrasound or CT every year or two) is standard. Even some larger tumors can be watched safely. A recent analysis of higher-risk angiomyolipomas found that growth rates ranged from about 0.08 cm per year for smaller tumors to 0.36 cm per year for larger ones, and that larger tumors grew significantly faster than smaller ones.¹³ The same study found that childbearing status in women did not significantly affect growth rates, which offers some reassurance to younger women under surveillance.

Surveillance does carry a psychological cost. Research on patients with small kidney masses (not limited to angiomyolipomas, but including them) suggests that being told you have a tumor and then being asked to wait can produce measurable distress. Patients on active surveillance have reported lower overall quality-of-life scores compared to those who had their tumor removed, driven mainly by lower physical health scores rather than mental health differences.¹⁴ Honest conversations with your doctor about what the imaging shows, what the actual risk of bleeding is, and how quickly the tumor is growing can help offset that anxiety.

Medication That Shrinks Tumors

Because angiomyolipomas are driven by overactive mTOR signaling, drugs that block mTOR can shrink them. Everolimus is the best-studied option and is approved specifically for TSC-associated angiomyolipomas. In the extension of a key randomized trial, patients who took everolimus for a median of about 29 months saw continued reductions in tumor volume. By week 96, roughly 82% of patients had achieved at least a 30% reduction in tumor size, and about 65% had achieved at least a 50% reduction. No angiomyolipoma-related bleeding occurred during the treatment period, and side effects were described as predictable and generally manageable.¹⁵

A significant limitation is that tumors tend to regrow when the drug is stopped, which means some patients face long-term or indefinite treatment. This has prompted interest in lower doses that might reduce side effects while still keeping tumors in check. A study comparing low-dose everolimus to conventional dosing found average tumor volume reductions of about 52% and 60% respectively, with no statistically significant difference between the groups.¹⁶ If these findings hold up in larger studies, lower doses could make long-term treatment more tolerable.

Embolization to Cut Off Blood Supply

Selective arterial embolization, or SAE, is a minimally invasive procedure in which an interventional radiologist threads a catheter into the artery feeding the tumor and injects material to block blood flow. It serves two purposes: stopping active bleeding in emergencies and shrinking tumors electively to reduce future bleeding risk. The procedure can be done with various materials, including tiny particles and ethanol-based mixtures, and both approaches have been shown to be safe and effective at decreasing tumor size and controlling hemorrhage.¹⁷

In a 10-year institutional experience, embolization reduced the median tumor size from 6.0 cm to 3.7 cm, and kidney function was not affected by the procedure.¹⁸ Most patients went home the same day. The most common side effect is post-embolization syndrome, a combination of pain, low-grade fever, and nausea that occurs in roughly a fifth to a third of patients and usually resolves within a few days. More serious complications like renal abscess can occur but are uncommon.¹⁹

One nuance worth understanding: embolization preferentially shrinks the blood vessel and muscle components of the tumor rather than the fat. The enhanced angiomyogenic component showed a median volume decrease of about 62% after embolization, while the fat component shrank by only about 18%.¹⁹ This means the tumor may still look sizable on follow-up imaging even when the dangerous, blood-vessel-rich portion has been successfully devascularized. Patients should know this so they are not alarmed by the post-procedure appearance.

Surgery and Ablation

When embolization is not feasible, when the tumor is very large, or when cancer cannot be excluded, surgery becomes the treatment. Partial nephrectomy, in which just the tumor and a margin of kidney tissue are removed, is strongly preferred over total nephrectomy because it preserves kidney function, carries an acceptable complication rate, and significantly reduces the chance of recurrence.²⁰ Complete kidney removal is generally reserved for cases with life-threatening hemorrhage that embolization cannot control or when malignancy is strongly suspected.

Even the epithelioid subtype, which has malignant potential, can sometimes be managed with partial nephrectomy if caught early, followed by yearly surveillance imaging rather than systemic therapy.²¹

Thermal ablation, particularly cryoablation (freezing the tumor in place through a needle), is another option for patients who are not good surgical candidates or who prefer a less invasive approach. Early evaluations suggest it is a safe and effective nephron-sparing alternative.²² The data on ablation for angiomyolipomas is still limited compared to embolization and surgery, but it fills a useful niche when other approaches are not ideal.

Pregnancy and Angiomyolipomas

Pregnancy creates a convergence of factors that make angiomyolipomas more dangerous. Rising estrogen and progesterone levels during pregnancy can accelerate tumor growth in hormone-receptor-positive tumors. Beyond hormonal effects, the increased blood volume and blood pressure of pregnancy alter the hemodynamics within the tumor and can promote aneurysm formation. Hydronephrosis from the relaxing effect of pregnancy hormones on the ureters and the pressure of the growing uterus adds further stress. During labor itself, increased intra-abdominal pressure makes a swollen angiomyolipoma more prone to rupture.²³

When a rupture does happen during pregnancy, the situation is clinically difficult. Surgery during pregnancy raises the risk of preterm delivery, and embolization involves radiation exposure to the fetus.²⁴ There is no established consensus on how to manage angiomyolipomas during pregnancy; decisions involve weighing maternal and fetal health, gestational age, available resources, and patient preferences. For women with known angiomyolipomas who are considering pregnancy, pre-conception imaging and a plan developed with both a urologist and an obstetrician are sensible precautions.

For women with TSC specifically, the picture is even less clear. A recent review concluded that the effect of pregnancy on TSC-associated angiomyolipoma size and complications is poorly understood, and that significantly more research is needed.²⁵ Given that TSC patients often have multiple and bilateral tumors, this knowledge gap is concerning.

The Epithelioid Variant and Malignant Potential

Classic angiomyolipomas are benign and stay that way. But a subtype called epithelioid angiomyolipoma (EAML) behaves differently. Instead of the typical mix of fat, muscle, and blood vessels, epithelioid angiomyolipomas contain a high proportion of large cells with abundant eosinophilic cytoplasm arranged in solid sheets. Increasing evidence shows this subtype is a potentially malignant tumor that can invade locally or, rarely, metastasize.²⁶

A multi-center follow-up study identified specific features that should trigger close surveillance and aggressive treatment. These red flags include a tumor size greater than 9 cm, tumor thrombus extending into a vein, epithelioid cells making up more than 70% of the tumor, atypical cells exceeding 60%, and the presence of necrosis. When these criteria are met, an integrated approach incorporating surgery, chemotherapy, and targeted therapy should be considered.²⁷

The epithelioid variant is also the one most likely to lack visible fat on imaging, making it harder to distinguish from renal cell carcinoma before biopsy. This overlap is one reason why urologists sometimes recommend removing a kidney mass surgically when imaging is indeterminate. If pathology after removal reveals an epithelioid angiomyolipoma with high-risk features, long-term surveillance imaging is essential. Some centers also consider everolimus or other mTOR inhibitors as adjunct therapy, given the shared genetic underpinning with classic angiomyolipomas, though evidence for systemic therapy in EAML specifically is still accumulating.

The distinction between classic and epithelioid angiomyolipomas matters for patients who have been told they have an angiomyolipoma and are reassured it is “just benign.” For the vast majority, that reassurance is warranted. But if a pathology report mentions epithelioid features, discussing the specific risk profile with a urologist or oncologist is worthwhile. The presence of those large, atypical cells changes the follow-up calculus from routine to attentive.